Consolidated Net Revenue: $372.8 million, an increase of 0.8% year-over-year. PYLARIFY Sales: $257.7 million, flat compared to the prior year. Precision Diagnostic Revenue: $104.4 million, flat year-over-year. DEFINITY Sales: $79.2 million, a 3.5% increase. TechneLite Revenue: $19.7 million, a decrease of 9.2% due to a brief supply issue. Gross Profit Margin: 67%, a decrease of 180 basis points. Operating Expenses: 28.3% of net revenue, 147 basis points higher than the prior year. Operating Profit: $144.3 million, a decrease of 7.1%. GAAP Net Income: $72.9 million. Adjusted Net Income: $109.5 million, a decrease of 7.5%. GAAP Diluted EPS: $1.02. Adjusted Diluted EPS: $1.53, a decrease of 9.5%. Operating Cash Flow: $107.6 million, down $19.7 million from the previous year. Free Cash Flow: $98.8 million, $20.1 million lower year-over-year. Cash and Cash Equivalents: $938.5 million at the end of Q1. Full-Year 2025 Revenue Guidance: $1.55 billion to $1.585 billion. Adjusted EPS Guidance for 2025: $6.60 to $6.70.

Warning! GuruFocus has detected 5 Warning Signs with RXO.

Release Date: May 07, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Lantheus Holdings Inc (NASDAQ:LNTH) announced two strategic acquisitions, Evergreen Theragnostics and Life Molecular Imaging, to enhance their radiopharmaceutical leadership and sustain long-term growth. The company plans to divest its SPECT business to SHINE Technologies, streamlining operations and focusing on PET radiodiagnostics and radiotherapeutic agents. PYLARIFY sales reached $258 million in the first quarter, with strategic partnerships securing the majority of revenue. The company has a strong cash position and disciplined capital allocation strategy, enabling continued investment in capabilities and pipeline expansion. Lantheus Holdings Inc (NASDAQ:LNTH) anticipates significant growth in the Alzheimer's radiodiagnostic market, with a potential total addressable market of $1.5 billion by the end of the decade.

Negative Points

PYLARIFY experienced a low single-digit decline in net price, and competitive pressures are expected to continue impacting smaller non-contracted sites. Gross profit margin decreased by 180 basis points due to strategic partnership contracting initiatives and a moly supply shortage. Operating expenses increased, reflecting investments in growth and efficiency initiatives, impacting the company's profitability. The divestiture of the SPECT business, while strategic, will result in the loss of a stable revenue contributor. The company's guidance for adjusted EPS was lowered due to updated expectations for PYLARIFY performance and increased R&D investments.

Story Continues

Q & A Highlights

Q: Can you elaborate on the competitive dynamics affecting PYLARIFY sales and the impact of strategic partnerships? A: Paul Blanchfield, President, explained that strategic partnerships with hospitals and imaging centers have stabilized the business amidst reimbursement changes. However, smaller non-contracted sites experienced competitive disruption due to reimbursement and product availability issues. Lantheus plans to maintain market leadership by expanding contracting efforts and product availability.

Q: What is the rationale behind divesting the SPECT business, and when can we expect the MK-6240 data? A: Brian Markison, CEO, stated that the SPECT business is not core to Lantheus' future growth, which focuses on molecular imaging and theranostic pairs. The divestiture will streamline operations and unlock value. The MK-6240 data is positive, and the company is preparing a new drug application, with plans to showcase the data soon.

Q: How does the SPECT divestiture impact resource allocation, and what are the drivers for the updated 2025 guidance? A: Robert Marshall, CFO, noted that the divestiture allows Lantheus to focus on growth areas like PET radiodiagnostics and radiotherapeutics. The updated guidance reflects a narrowed range due to PYLARIFY's performance, with expectations of healthy dose volumes for the year.

Q: What is the expected impact of the acquisitions on 2026 growth, and is double-digit revenue growth still anticipated? A: Brian Markison, CEO, confirmed that double-digit growth is expected in 2026, driven by potential launches of OCTEVY, PNT2003, MK-6240, and the full annualization of Neuraceq, alongside continued growth of PYLARIFY and DEFINITY.

Q: How do you view the long-term opportunity for GRPR-targeting imaging and therapy in prostate cancer? A: Brian Markison, CEO, explained that GRPR expression is similar to PSMA in early prostate cancer, offering potential for imaging and therapy. The diagnostic agent is in Phase 2, and the therapeutic candidate is progressing towards clinical trials, with potential use in combination with other therapies.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments